Table 1.
Distribution of phase II trial clinical, molecular, and demographic characteristics (n = 42)
| Patient characteristics | Frequency (%) |
|---|---|
| Gender | |
| Female | 10 (23.8) |
| Male | 32 (76.2) |
| Race | |
| White | 30 (71.4) |
| African American or Black | 7 (16.7) |
| Asian | 1 (2.4) |
| American Indian or Alaska native | 1 (2.4) |
| Unknown | 3 (7.1) |
| Age range (years) | |
| 40–49 | 6 (14.3) |
| 50–59 | 17 (40.5) |
| 60–69 | 14 (33.3) |
| 70–79 | 2 (4.8) |
| >79 | 2 (4.8) |
| Unknown | 1 (2.4) |
| Age (years) | |
| N | 42 |
| Median | 59 |
| Range | 42–82 |
| Status | |
| Alive | 4 (9.5) |
| Dead | 36 (85.7) |
| Unknown | 2 (4.8) |
| Clinical measures | |
| Primary tumor site | |
| OP (oropharynx) | 16 (38.1) |
| Non-OP (all other sites) | 24 (57.1) |
| Not available | 2 (4.8) |
| Genotype | |
| FF | 14 (33.3) |
| VF | 19 (45.2) |
| VV | 3 (7.1) |
| Not available | 6 (14.3) |
| ADCC performed | |
| No | 17 (40.0) |
| Yes | 25 (60.0) |
| ADCC | |
| Noninducible | 17 (69.2) |
| Inducible | 8 (30.8) |
| Prior chemoradiation | |
| No | 3 (7.1) |
| Yes | 36 (85.7) |
| Unknown | 3 (7.1) |
| Prior surgery | |
| No | 14 (33.3) |
| Yes | 25 (59.5) |
| Unknown | 3 (7.1) |
| p16 staining | |
| Negative | 7 (16.7) |
| Positive | 6 (14.3) |
| Not tested | 29 (69.0) |
| ECOG status | |
| 0 | 13 (30.9) |
| 1 | 27 (64.3) |
| Unknown | 2 (4.8) |
| Disease location | |
| Local only | 5 (11.9) |
| Metastatic only | 21 (50.0) |
| Local and metastatic | 14 (33.3) |
| Unknown | 2 (4.8) |